Back to Search
Start Over
Genetic underpinnings of tardive dyskinesia: passing the baton to pharmacogenetics.
- Source :
-
Pharmacogenomics [Pharmacogenomics] 2008 Sep; Vol. 9 (9), pp. 1285-306. - Publication Year :
- 2008
-
Abstract
- Manifestation of tardive dyskinesia (TD) among schizophrenia subjects on long-term antipsychotic treatment with typical drugs has been a clinical concern. Despite its association with extrapyramidal symptoms, typical drugs are still routinely prescribed globally though marginally superior atypical drugs have long been available. The genetic component in the etiology of TD is well documented. Search for these determinants has led to a few consensus associations of CYP2D6 *10, CYP1A2*1F, DRD2 Taq1A (rs1800497), DRD3 Ser9Gly (rs6280) and MnSOD Ala9Val (rs4880) variants with TD. However, translation of these observations into the clinic has not been achieved so far. This review discusses the salient features of TD etiopathology, current status of TD genetics, interactions between genetic and nongenetic factors, some major drawbacks, challenges and expected focus in TD research over the next decade, with emphasis on pharmacogenetics.
- Subjects :
- Antipsychotic Agents adverse effects
Antipsychotic Agents pharmacology
Antipsychotic Agents therapeutic use
Dyskinesia, Drug-Induced prevention & control
Genetic Predisposition to Disease genetics
Genetic Variation drug effects
Humans
Pharmacogenetics methods
Polymorphism, Genetic drug effects
Polymorphism, Genetic genetics
Schizophrenia drug therapy
Schizophrenia genetics
Dyskinesia, Drug-Induced genetics
Genetic Variation genetics
Pharmacogenetics trends
Subjects
Details
- Language :
- English
- ISSN :
- 1744-8042
- Volume :
- 9
- Issue :
- 9
- Database :
- MEDLINE
- Journal :
- Pharmacogenomics
- Publication Type :
- Academic Journal
- Accession number :
- 18781856
- Full Text :
- https://doi.org/10.2217/14622416.9.9.1285